Glaukos Raises Annual Revenue Guidance as Sales Growth Accelerates
The medical device maker raised its full-year net sales forecast to as high as $700 million
Glaukos Corp. (GKOS) reported second-quarter net sales of $185.6 million, representing a 50% increase year-over-year.
The company experienced an acceleration in growth compared to the first quarter of 2026, when net sales rose 41% year-over-year to $150.6 million. This trajectory was supported by a rise in margins and a narrowing of operating losses.
U.S. Glaucoma net sales rose 64% year-over-year to $118.5 million. This growth rate accelerated from the 58% year-over-year increase seen in the first quarter. International Glaucoma net sales grew 17% year-over-year during the period.
Corneal Health net revenues grew 48% year-over-year to $30.4 million. This result included $11 million in sales from the newly launched Epioxa.
Non-GAAP gross margin expanded to approximately 85% in the second quarter, up from 84% in the first quarter and 83% in the second quarter of 2025. GAAP gross margin rose to approximately 82%, compared to 78% in both the prior quarter and the same period last year.
Operating expenses increased as the company scaled. SG&A expenses rose 39% year-over-year to $116.1 million, while R&D expenses increased 40% year-over-year to $51.3 million. The company also reported an acquired in-process R&D charge of $1.5 million.
Despite the higher spending, the non-GAAP operating loss narrowed to $7.6 million. This follows a loss of $10.5 million in the first quarter and $16.6 million in the second quarter of 2025.
Glaukos raised its full-year 2026 net sales guidance to a range of $680 million to $700 million. The company previously projected net sales between $620 million and $635 million.